JP2000511537A - 黄色ブドウ球菌における毒力因子の発現の阻止 - Google Patents

黄色ブドウ球菌における毒力因子の発現の阻止

Info

Publication number: JP2000511537A
Authority: JP; Japan
Prior art keywords: peptide; cys; cooh; aureus; amino acid
Prior art date: 1996-05-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP09542779A

Other languages

English (en)

Japanese (ja)

Inventor

ノヴィック、リチャード・ピー

ジ、グァンヨン

ビーヴィス、ロナルド

Original Assignee

ニューヨーク・ユニヴァーシティ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-22

Filing date

1997-05-22

Publication date

2000-09-05

1997-05-22 Application filed by ニューヨーク・ユニヴァーシティ filed Critical ニューヨーク・ユニヴァーシティ

2000-09-05 Publication of JP2000511537A publication Critical patent/JP2000511537A/ja

Status Ceased legal-status Critical Current

Links

239000000304 virulence factor Substances 0.000 title abstract description 15
230000007923 virulence factor Effects 0.000 title abstract description 15
241000191967 Staphylococcus aureus Species 0.000 title description 3
230000005764 inhibitory process Effects 0.000 title description 3
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 91
238000000034 method Methods 0.000 claims abstract description 24
230000035897 transcription Effects 0.000 claims abstract description 20
238000013518 transcription Methods 0.000 claims abstract description 20
208000015181 infectious disease Diseases 0.000 claims abstract description 13
201000010099 disease Diseases 0.000 claims abstract description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
241000894006 Bacteria Species 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 18
150000001413 amino acids Chemical class 0.000 claims description 17
241000191982 Staphylococcus hyicus Species 0.000 claims description 8
150000007970 thio esters Chemical class 0.000 claims description 8
241001134656 Staphylococcus lugdunensis Species 0.000 claims description 7
-1 cyclic thioester Chemical class 0.000 claims description 7
241001147695 Staphylococcus caprae Species 0.000 claims description 5
241000191965 Staphylococcus carnosus Species 0.000 claims description 5
241000147121 Staphylococcus lentus Species 0.000 claims description 5
241001147736 Staphylococcus capitis Species 0.000 claims description 4
241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
241000191984 Staphylococcus haemolyticus Species 0.000 claims description 4
241000192087 Staphylococcus hominis Species 0.000 claims description 4
241001147689 Staphylococcus kloosii Species 0.000 claims description 4
241000192097 Staphylococcus sciuri Species 0.000 claims description 4
241000191973 Staphylococcus xylosus Species 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 12
125000000896 monocarboxylic acid group Chemical group 0.000 claims 12
241000191978 Staphylococcus simulans Species 0.000 claims 3
108010069514 Cyclic Peptides Proteins 0.000 claims 1
102000001189 Cyclic Peptides Human genes 0.000 claims 1
241000191940 Staphylococcus Species 0.000 claims 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
101150118631 agrA gene Proteins 0.000 abstract description 12
230000002401 inhibitory effect Effects 0.000 abstract description 8
239000008194 pharmaceutical composition Substances 0.000 abstract 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
210000004027 cell Anatomy 0.000 description 13
230000000694 effects Effects 0.000 description 13
108091030066 RNAIII Proteins 0.000 description 11
239000003112 inhibitor Substances 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
230000003213 activating effect Effects 0.000 description 6
239000003242 anti bacterial agent Substances 0.000 description 6
229940088710 antibiotic agent Drugs 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000003016 pheromone Substances 0.000 description 6
230000004913 activation Effects 0.000 description 5
239000012228 culture supernatant Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
241000295644 Staphylococcaceae Species 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
238000003556 assay Methods 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
241000894007 species Species 0.000 description 4
229960004799 tryptophan Drugs 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101710172087 Class B acid phosphatase Proteins 0.000 description 3
102100033026 Transmembrane protein 102 Human genes 0.000 description 3
239000012911 assay medium Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010065152 Coagulase Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
244000000059 gram-positive pathogen Species 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960004452 methionine Drugs 0.000 description 2
230000008569 process Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
LZMSXDHGHZKXJD-VJANTYMQSA-N trypanothione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H]1CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(=O)NCCCNCCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-VJANTYMQSA-N 0.000 description 2
230000001018 virulence Effects 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
241000766754 Agra Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000973043 Macrococcus caseolyticus Species 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010036410 Postoperative wound infection Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000031650 Surgical Wound Infection Diseases 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
206010058041 Wound sepsis Diseases 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
229940032049 enterococcus faecalis Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000012130 whole-cell lysate Substances 0.000 description 1
AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Chemical And Physical Treatments For Wood And The Like (AREA)
Electrotherapy Devices (AREA)
Air Conditioning Control Device (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Heat Treatment Of Steel (AREA)
Control Of Combustion (AREA)

JP09542779A 1996-05-22 1997-05-22 黄色ブドウ球菌における毒力因子の発現の阻止 Ceased JP2000511537A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65122696A	1996-05-22	1996-05-22
US08/651,226		1996-05-22
PCT/US1997/008791 WO1997044349A1 (en)	1996-05-22	1997-05-22	BLOCKING EXPRESSION OF VIRULENCE FACTORS IN $i(S. AUREUS)

Publications (1)

Publication Number	Publication Date
JP2000511537A true JP2000511537A (ja)	2000-09-05

Family

ID=24612055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP09542779A Ceased JP2000511537A (ja)	1996-05-22	1997-05-22	黄色ブドウ球菌における毒力因子の発現の阻止

Country Status (8)

Country	Link
EP (1)	EP0932613B1 (de)
JP (1)	JP2000511537A (de)
AT (1)	ATE290548T1 (de)
AU (1)	AU735283B2 (de)
CA (1)	CA2256465A1 (de)
DE (1)	DE69732709T2 (de)
PT (1)	PT932613E (de)
WO (1)	WO1997044349A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2014221774A (ja) *	2007-10-25	2014-11-27	ザスクリプスリサーチインスティテュート	抗体媒介による細菌のクオラムセンシングの破壊
JP2020536494A (ja) *	2017-08-31	2020-12-17	ザリージェンツオブザユニバーシティオブカリフォルニア	皮膚の酵素活性を制御する分子的細菌療法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9724859D0 (en) *	1997-11-26	1998-01-21	Univ Nottingham	Compounds and their use as antibacterial agents
US7323179B2 (en)	1997-12-19	2008-01-29	Naomi Balaban	Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US6291431B1 (en)	1997-12-19	2001-09-18	Panorama Research	Methods and compositions for the treatment and prevention of Staphylococcal infections
US7534857B2 (en)	1997-12-19	2009-05-19	Centegen, Inc.	Methods and compositions for the treatment and prevention of staphylococcal infections
CA2331888A1 (en) *	1998-06-24	1999-12-29	The Rockefeller University	Novel staphylococcus peptides for bacterial interference
US6337385B1 (en)	1998-06-24	2002-01-08	The Rockefeller University	Staphylococcus peptides for bacterial interference
EP1188831B1 (de) *	1998-09-15	2007-12-05	Naomi Balaban	Ziel des RNAIII activierenden Proteines (TRAP)
EP1862549A3 (de)	1998-09-15	2008-02-13	Naomi Balaban	Target eines RNAIII-aktivierenden Proteins (TRAP)
US6747129B1 (en)	1998-09-15	2004-06-08	The Regents Of The University Of California	Target of RNAIII activating protein(TRAP)
JP2003522153A (ja) *	2000-02-10	2003-07-22	インターミューンインコーポレイテッド	ブドウ球菌属ビルレンスの新規アミノ酸インヒビターおよびペプチドインヒビター
AU2001234147A1 (en) *	2000-02-23	2001-09-03	Kureha Chemical Industry Co. Ltd.	Plant growth promoters and method of promoting plant growth
US7824691B2 (en)	2005-04-04	2010-11-02	Centegen, Inc.	Use of RIP in treating staphylococcus aureus infections
ES2682595T3 (es)	2015-03-23	2018-09-21	Eberhard Karls Universität Tübingen	Nuevo compuesto antiinfeccioso
US10821167B2 (en) *	2016-02-02	2020-11-03	Unm Rainforest Innovations	VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors
KR102286075B1 (ko) *	2019-09-27	2021-08-05	코스맥스 주식회사	스타필로코커스 렌투스 st-2 균주 및 그의 피부 상태 개선 용도
KR102195998B1 (ko) *	2019-09-27	2020-12-29	코스맥스 주식회사	스타필로코커스 시뮬란스 st-9 균주 및 그의 피부 상태 개선 용도
KR102199062B1 (ko) *	2019-09-27	2021-01-06	코스맥스 주식회사	스타필로코커스 자일로서스 st-10 균주 및 그의 피부 상태 개선 용도
CN118931767B (zh) *	2024-07-24	2025-03-25	内蒙古医科大学附属医院(内蒙古自治区心血管研究所)	一株纹带棒状杆菌nmgcs43及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3825995A (en) *	1994-10-04	1996-04-26	New York University	Blocking expression of virulence factors in s. aureus

1997
- 1997-05-22 JP JP09542779A patent/JP2000511537A/ja not_active Ceased
- 1997-05-22 AU AU32117/97A patent/AU735283B2/en not_active Ceased
- 1997-05-22 PT PT97927727T patent/PT932613E/pt unknown
- 1997-05-22 CA CA002256465A patent/CA2256465A1/en not_active Abandoned
- 1997-05-22 AT AT97927727T patent/ATE290548T1/de not_active IP Right Cessation
- 1997-05-22 EP EP97927727A patent/EP0932613B1/de not_active Expired - Lifetime
- 1997-05-22 DE DE69732709T patent/DE69732709T2/de not_active Expired - Fee Related
- 1997-05-22 WO PCT/US1997/008791 patent/WO1997044349A1/en not_active Ceased

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2014221774A (ja) *	2007-10-25	2014-11-27	ザスクリプスリサーチインスティテュート	抗体媒介による細菌のクオラムセンシングの破壊
JP2018021021A (ja) *	2007-10-25	2018-02-08	ザスクリプスリサーチインスティテュート	抗体媒介による細菌のクオラムセンシングの破壊
JP2020536494A (ja) *	2017-08-31	2020-12-17	ザリージェンツオブザユニバーシティオブカリフォルニア	皮膚の酵素活性を制御する分子的細菌療法
JP7373176B2 (ja)	2017-08-31	2023-11-02	ザリージェンツオブザユニバーシティオブカリフォルニア	皮膚の酵素活性を制御する分子的細菌療法
JP2024009974A (ja) *	2017-08-31	2024-01-23	ザリージェンツオブザユニバーシティオブカリフォルニア	皮膚の酵素活性を制御する分子的細菌療法
JP7720639B2 (ja)	2017-08-31	2025-08-08	ザリージェンツオブザユニバーシティオブカリフォルニア	皮膚の酵素活性を制御する分子的細菌療法
JP7720639B6 (ja)	2017-08-31	2025-09-18	ザリージェンツオブザユニバーシティオブカリフォルニア	皮膚の酵素活性を制御する分子的細菌療法

Also Published As

Publication number	Publication date
EP0932613A4 (de)	2002-01-09
ATE290548T1 (de)	2005-03-15
PT932613E (pt)	2005-06-30
WO1997044349A1 (en)	1997-11-27
DE69732709T2 (de)	2006-06-29
EP0932613A1 (de)	1999-08-04
AU3211797A (en)	1997-12-09
CA2256465A1 (en)	1997-11-27
AU735283B2 (en)	2001-07-05
EP0932613B1 (de)	2005-03-09
DE69732709D1 (de)	2005-04-14

Legal Events

Date	Code	Title	Description
2004-06-10	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040521
2006-07-25	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725
2007-01-04	A313	Final decision of rejection without a dissenting response from the applicant	Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20061218
2007-01-30	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070130

Publication	Publication Date	Title
JP2000511537A (ja)	2000-09-05	黄色ブドウ球菌における毒力因子の発現の阻止
JP6355792B2 (ja)	2018-07-11	抗菌性ファージ、ファージペプチド、及びそれらの使用方法
JP2010207227A (ja)	2010-09-24	新規な抗菌性ポリペプチド及び使用方法
WO1995003413A1 (en)	1995-02-02	High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins
US6447786B1 (en)	2002-09-10	Blocking expression of virulence factors in S. aureus
US5939279A (en)	1999-08-17	Inhibition of bacterial binding by high-mannose oligosaccharides
JP2010011852A (ja)	2010-01-21	細菌フェロモンおよびその使用
WO2003016339A1 (fr)	2003-02-27	Derive peptidique antibacterien de peau de grenouille
CN102603885A (zh)	2012-07-25	防御素及其在制备抗菌药物中的应用
CN112778424B (zh)	2022-07-26	嵌合肽r7及其应用
CN115433263B (zh)	2025-03-14	人类口腔放线菌来源的防御素、及其编码基因和用途
US20100173842A1 (en)	2010-07-08	Vaccine for staphylococcal infections
CN1569889A (zh)	2005-01-26	能与金葡菌自分泌的rnaiii激活蛋白结合的环多肽及其医药用途
KR20230159563A (ko)	2023-11-21	장독소원성 박테로이데스 프라길리스의 증식을 억제하기 위한 조성물 및 방법
AU2015255318A1 (en)	2015-12-03	Antibacterial phage, phage peptides and methods of use thereof
CN119585296A (zh)	2025-03-07	对包括金黄色葡萄球菌的葡萄球菌具有强力的溶菌活性的抗菌蛋白
Galoyan	2012	Antibacterial and Antiviral Activity of PRP-1 (Galarmin) and Some Immunological Mechanisms of its Action
BRPI0613026A2 (pt)	2012-01-03	composiÇço, fragmento de nucleotÍdeo, constructo de dna recombinante, mÉtodo para produzir proteÍna, composiÇço farmacÊutica e mÉtodo para uso da mesma, formulaÇço, mÉtodo de administrar composiÇço farmacÊutica, mÉtodo de prevenÇço e controle de infecÇÕes associadas a staphylococcus
CN1235053A (zh)	1999-11-17	霍乱弧菌口服活菌苗